Schrodinger
SDGRSchrodinger, Inc. provides a differentiated, physics-based computational platform that transforms the discovery of novel molecules for drug development and materials applications.
Earnings
Next report
Nov 4, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Schrodinger, Inc. provides a differentiated, physics-based computational platform that transforms the discovery of novel molecules for drug development and materials applications. The company's platform enables more rapid and cost-effective molecule design by accurately predicting critical properties before chemical synthesis. Their business model combines a high-margin software licensing business with a pipeline of collaborative and proprietary drug discovery programs.
A leading provider of physics-based molecular modeling software with a unique dual-track strategy of software licensing and internal drug development.
FAQ
- What is Schrodinger's market cap?
- Schrodinger (SDGR) has a market capitalization of $1.7B and trades on NASDAQ.
- What is Schrodinger's revenue and profitability?
- Schrodinger generated $259.0M in trailing twelve-month revenue with a net loss of $130.0M, representing a net margin of -68.5%. Gross margin stands at 56.9%, with free cash flow of $59.7M. The latest reported period is Q2 2026.
- Who are Schrodinger's competitors?
- Schrodinger's key competitors include Certara, Simulation Plus, Sutro Biopharma, Inc., and others. These companies compete in similar markets and product categories.
- Who does Schrodinger partner with?
- Schrodinger's notable partners include Novartis Pharma AG, Bristol-Myers Squibb, Sanofi.
- What subsidiaries does Schrodinger have?
- Schrodinger's subsidiaries include Schrödinger Therapeutics Group.
- Where is Schrodinger headquartered?
- Schrodinger is headquartered in United States of America and employs approximately 787 people. It has been publicly traded since 2020.
